Three Strategies for Creating a Sustainable Recruiting Model
What should pathology groups and labs do in order to attract and maintain clinical talent in today’s economy?
Laboratory Industry Report
Keeps You Up-to-Date on Lab Business and Competitive Strategy, Market Trends and Opportunities, and M&A and Investment Activity in Today’s Diagnostic Lab Industry
Subscribe today for access to
Articles and Reports
Latest Articles
M&A & Strategic Deals: Dealmaking Shows New Signs of Life but FTC Scrutiny Casts a Dark Shadow
After a significant lull, M&As in the lab diagnostics space heated up in May, with several key deals announced.
June 2023 FDA Watch
So far, it appears many post-PHE COVID-19 tests will be panels for detecting and differentiating among multiple respiratory viruses.
DX Deals: Large Healthcare Bankruptcies Rebound from Pandemic Lull
A recent report offers new insight into bankruptcy trends within the sector starting before the COVID-19 pandemic.
Medicare Expands Coverage of Molecular Cancer Screening Tests
In terms of Medicare coverage, 2023 is shaping up to be a fruitful year—here are five of the most significant approvals so far.
Growth of Medical & Consumer Debt Poses New Challenges for Collections
Increasing medical and consumer debt is likely to get worse, meaning billing and collections may get even tougher for labs.
Hostile Regulatory Environment Further Chills Diagnostics Market
The biggest story in M&A dealmaking continues to be the deal that’s being undone—Illumina’s acquisition of GRAIL.
A Timeline of 2023 Lab Company Layoffs So Far
The wave of layoffs, which began last year with the declines in COVID-19 testing sales, has gathered momentum in 2023.
Bill Would Require Medicare to Cover New Breakthrough Devices for at Least 4 Years
The bill is designed to provide Medicare patients faster access to innovative technology approved by the FDA.
Lab Companies Team with Nonprofits on Test Development, Access, & Awareness
April was among the busiest months, in recent memory, in terms of both deal volume and significance in the diagnostics industry.
OTC COVID-19/Influenza Test Approval Comes Too Late to Save Lucira Health
No company better embodies the vicissitudes of running a COVID-19-focused diagnostics business during the pandemic period than Lucira Health.
FDA Keeps COVID-19 EUA Pipeline Open While Working toward Transition
HHS secretary takes action to ensure that EUAs remain in effect until the “significant potential” for a COVID-19 PHE no longer exists.
Lab Companies Turn to Product Integrations to Cut Costs, Risks, & Time
Product integration collaborations have become increasingly common, with five such deals being announced between February and mid-March.
